Hutchinson-Gilford Progeria síndrome

Authors

Keywords:

Congenital genetic diseases, Progeria, Premature aging, Lamin type A.

Abstract

Hutchinson-Gilford Progeria Syndrome is a disease characterized by premature aging in children, due to a mutation in the Lamina type A, gene involved in cellular mitosis. In the present work, with the aim of spreading the knowledge of this disease, the processes involved in its development, the scientific advances, and the scope of new therapeutic treatments were summarized. The review was carried out by consulting articles in Spanish and English using the Pubmed and Google Academic search engines. The updating of health personnel on congenital genetic diseases is of vital importance to improve their detection, care and management.

 

Downloads

Download data is not yet available.

Author Biographies

Luis Alberto De Sales Palestina, Universidad de las Américas Puebla

Estudiante del Doctorado en Biomedicina Molecular. Departamento de Ciencias Químico-Biológicas. Universidad de las Américas Puebla

Erika Palacios Palacios-Rosas, Universidad de las Américas Puebla

PhD Pharmacology and Physiology, Universidad Autónoma de Madrid Associate Senior Professor, Health Sciences Department. Universidad de las Américas Puebla

References

1. Santiago Fernández O, Osorio FG, Quesada V, Rodríguez F, Basso S, Maeso D, et al. Development of a CRISPR/Cas9-based therapy for Hutchinson-Gilford progeria syndrome. Nat Med. 2019; 25(3): 423-6.

2. Rankin J, Ellard S. The laminopathies: A clinical review. Clin Genet. 2006; 70(4): 261–74.

3. Kang S, Yoon MH, Park BJ. Laminopathies; Mutations on single gene and various human genetic diseases. BMB Rep. 2018; 51(7): 327-37.

4. Benedicto I, Dorado B, Andrés V. Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models. Cells. 2021; 10: 1157.

5. Panigrahi RG, Panigrahi A, Vijayakumar P, Choudhury P, Bhuyan SK, Bhuyan R, et al. Hutchinson-gilford progeria syndrome: a rare genetic disorder. Case Rep Dent. 2013; 2013: 631378.

6. S Chawla GS, Agrawal PM, Dhok A. Progeria: an extremely unusual disorder. Skeletal Radiol. 2017; 46(8): 1149-53.

7. Erdos MR, Cabral WA, Tavarez UL, Cao K, Gvozdenovic Jeremic J, Narisu N, et al. A targeted antisense therapeutic approach for Hutchinson–Gilford progeria syndrome. Nat Med. 2021 Mar 1; 27(3): 536–45.

8. Donnaloja F, Carnevali F, Jacchetti E, Raimondi MT. Lamin A/C Mechanotransduction in Laminopathies. Cells. 2020; 9(5): 1306-39.

9. Atalaia A, Ben Yaou R, Wahbi K, Sandre Giovannoli A. de, Vigouroux C, Bonne G. Laminopathies’ Treatments Systematic Review: A Contribution Towards a

‘Treatabolome. J Neuromuscul Dis. 2021; 8(3): 419-39.

10. Moiseeva O, Lopes Paciencia S, Huot G, Lessard F, Ferbeyre G. Permanent farnesylation of lamin A mutants linked to progeria impairs its phosphorylation at serine 22 during interphase. Aging (Albany NY). 2016; 8(2): 366-81.

11. Gonzalo S, Kreienkamp R, Askjaer P. Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations. Ageing Res Rev. 2017 Jan; 33: 18-29.

12. Sinha JK, Ghosh S, Raghunath M. Progeria: a rare genetic premature ageing disorder. Indian J Med Res. 2014; 139(5): 667-74.

13. Tae Kang H, Tae Park J, Choi K, Choi HJC, Won Jung C, Ree Kim G, et al. Chemical screening identifies ROCK as a target for recovering mitochondrial function in Hutchinson-Gilford progeria syndrome. Aging Cell. 2017; 16(3): 541-50.

14. Gordon LB, Rothman FG, López Otín C, Misteli T. Progeria: a paradigm for translational medicine. Cell. 2014 Jan 30; 156(3): 400-7.

15. Eisch V, Lu X, Gabriel D, Djabali K. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts. Oncotarget. 2016; 7(17): 24700 - 18.

16. Ashapkin VV, Kutueva LI, Kurchashova SY, Kireev II. Are There Common Mechanisms Between the Hutchinson-Gilford Progeria Syndrome and Natural Aging? Front Genet. 2019 May 15; 10: 455.

17. Wang S, Yang Z, Xu Z, Chu Y, Liang Y, Wei L, et al. Clinical and genetic features of children with Hutchinson-Gilford progeria syndrome: a case series and a literature review. J Eur Acad Dermatology Venereol. 2021; 35(6): e387–e91.

18. Rork JF, Huang JT, Gordon LB, Kleinman M, Kieran MW, Liang MG. Initial Cutaneous Manifestations of Hutchinson-Gilford Progeria Syndrome. Pediatr Dermatol. 2014; 31(2): 196 - 202.

19. Domingo DL, Trujillo MI, Council SE, Merideth MA, Gordon LB, Wu T, et al. Hutchinson-Gilford progeria syndrome: Oral and craniofacial phenotypes. Oral Dis ]. 2009; 15(3): 187-95.

20. Samsudin DD, Devaera Y. Laporan kasus: Gizi Buruk Sekunder Akibat Kelainan Genetik: Hutchinson-Gilford Progeria Syndrome. Maj Kedokt UKI. 2018; 34(2): 82–9.

21. Kieran MW, Gordon L, Kleinman M. New approaches to Progeria. Pediatrics. 2007; 120(4): 834–41.

22. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith ACM, Perry MB, et al. Phenotype and Course of Hutchinson–Gilford Progeria Syndrome. N Engl J Med. 2008 Feb 7; 358(6): 592-604.

23. Hamczyk MR, Villa Bellosta R, Gonzalo P, Andrés Manzano MJ, Nogales P, Bentzon JF, et al. Vascular Smooth Muscle–Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome. Circulation. 2018; 138(3): 266-82.

24. Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2013; 34(5): 1091-7.

25. Saad Ahmed M, Ikram S, Bibi N, Mir A. Hutchinson-Gilford Progeria Syndrome: A Premature Aging Disease. Mol Neurobiol. 2018; 55(5): 4417–27.

Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132: 249-64.

26. Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132: 249-64.

27. Progeria - Pediatría - Manual MSD versión para profesionales. [Internet]. 2021 [citado 14/11/2021]. Disponible en: https://blogs.sld.cu/marionod/2017/11/25/manual-msd-version-para-profesionales/

28. Beauregard Lacroix E, Salian S, Kim H, Ehresmann S, DʹAmours G, Gauthier J, et al. A variant of neonatal progeroid syndrome, or Wiedemann–Rautenstrauch syndrome, is associated with a nonsense variant in POLR3GL. Eur J Hum Genet. 2020; 28(4): 461–8.

29. Acosta Aragón MA, Sierra Zúñiga MF, Sotelo Muñoz NF. Síndrome de Werner: a propósito de un caso probable. Medicina & Laboratorio. 2017; 23(9): 485-92.

30. Blondel S, Jaskowiak AL, Egesipe AL, Le Corf A, Navarro C, Cordette V, et al. Induced Pluripotent Stem Cells Reveal Functional Differences Between Drugs Currently Investigated in Patients With Hutchinson-Gilford Progeria Syndrome. Stem Cells Transl Med. 2014; 3(4): 510-9.

31. Cubria MB, Suarez S, Masoudi A, Oftadeh R, Kamalapathy P, DuBose A, et al. Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups. Proc Natl Acad Sci USA. 2020; 117(22): 12029.

32. Aboud B. Is Rapamycin an Effective Anti-aging Drug? Sci J Lander Coll Arts Sci. 2020; 13(2): 36-41.

33. Mattioli E, Andrenacci D, Mai A, Valente S, Robijns J, De Vos WH, et al. Statins and Histone Deacetylase Inhibitors Affect Lamin A/C - Histone Deacetylase 2 Interaction in Human Cells. Front Cell Dev Biol. 2019 Jan 31; 7(6): 1-19.

34. Larrieu D, Britton S, Demir M, Rodriguez R, Jackson SP. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014; 344(6183): 527-32.

35. Beljanski V. Lonafarnib. XPharm Compr Pharmacol Ref. 2021; 1–7.

36. Frankel D, Delecourt V, Harhouri K, Sandre Giovannoli A. de, Lévy N, Kaspi E, et al. MicroRNAs in hereditary and sporadic premature aging syndromes and other laminopathies. Aging Cell. 2018 Aug; 17(4): e12766.

Downloads

Published

2022-11-03

How to Cite

1.
De Sales Palestina LA, Palacios-Rosas EP. Hutchinson-Gilford Progeria síndrome. RM [Internet]. 2022 Nov. 3 [cited 2025 Jun. 7];26(5):e2521. Available from: https://revmultimed.sld.cu/index.php/mtm/article/view/2521

Issue

Vol. 26 No. 5 (2022): Septiembre - Octubre

Section

REVISIONES BIBLIOGRÁFICAS

License

Avisos de derechos de autor propuestos por Creative Commons

1. Política propuesta para revistas que ofrecen acceso abierto

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).